QQQ   309.58 (+0.14%)
AAPL   121.42 (-0.52%)
MSFT   227.61 (+0.02%)
FB   258.41 (+1.17%)
GOOGL   2,028.26 (+0.84%)
TSLA   643.25 (-1.52%)
AMZN   3,018.93 (+0.46%)
NVDA   507.29 (-0.96%)
BABA   234.02 (-0.95%)
CGC   32.04 (-3.61%)
GE   13.80 (+2.68%)
MU   87.18 (-2.17%)
NIO   40.03 (-3.61%)
AMD   80.69 (-0.21%)
T   29.23 (+1.78%)
F   12.30 (+1.07%)
ACB   9.98 (-4.59%)
DIS   190.14 (-1.10%)
BA   233.02 (+1.95%)
NFLX   521.04 (+0.07%)
PFE   34.71 (+0.93%)
QQQ   309.58 (+0.14%)
AAPL   121.42 (-0.52%)
MSFT   227.61 (+0.02%)
FB   258.41 (+1.17%)
GOOGL   2,028.26 (+0.84%)
TSLA   643.25 (-1.52%)
AMZN   3,018.93 (+0.46%)
NVDA   507.29 (-0.96%)
BABA   234.02 (-0.95%)
CGC   32.04 (-3.61%)
GE   13.80 (+2.68%)
MU   87.18 (-2.17%)
NIO   40.03 (-3.61%)
AMD   80.69 (-0.21%)
T   29.23 (+1.78%)
F   12.30 (+1.07%)
ACB   9.98 (-4.59%)
DIS   190.14 (-1.10%)
BA   233.02 (+1.95%)
NFLX   521.04 (+0.07%)
PFE   34.71 (+0.93%)
QQQ   309.58 (+0.14%)
AAPL   121.42 (-0.52%)
MSFT   227.61 (+0.02%)
FB   258.41 (+1.17%)
GOOGL   2,028.26 (+0.84%)
TSLA   643.25 (-1.52%)
AMZN   3,018.93 (+0.46%)
NVDA   507.29 (-0.96%)
BABA   234.02 (-0.95%)
CGC   32.04 (-3.61%)
GE   13.80 (+2.68%)
MU   87.18 (-2.17%)
NIO   40.03 (-3.61%)
AMD   80.69 (-0.21%)
T   29.23 (+1.78%)
F   12.30 (+1.07%)
ACB   9.98 (-4.59%)
DIS   190.14 (-1.10%)
BA   233.02 (+1.95%)
NFLX   521.04 (+0.07%)
PFE   34.71 (+0.93%)
QQQ   309.58 (+0.14%)
AAPL   121.42 (-0.52%)
MSFT   227.61 (+0.02%)
FB   258.41 (+1.17%)
GOOGL   2,028.26 (+0.84%)
TSLA   643.25 (-1.52%)
AMZN   3,018.93 (+0.46%)
NVDA   507.29 (-0.96%)
BABA   234.02 (-0.95%)
CGC   32.04 (-3.61%)
GE   13.80 (+2.68%)
MU   87.18 (-2.17%)
NIO   40.03 (-3.61%)
AMD   80.69 (-0.21%)
T   29.23 (+1.78%)
F   12.30 (+1.07%)
ACB   9.98 (-4.59%)
DIS   190.14 (-1.10%)
BA   233.02 (+1.95%)
NFLX   521.04 (+0.07%)
PFE   34.71 (+0.93%)
Log in

Piper Sandler's rating of Revance Therapeutics, Inc. on 2/25/2020

unlock icon Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.